Novartis AG Company Profile
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Novartis at a glance
Novartis AG (NYSE: NVS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Basel, Switzerland. Novartis is led by Dr. Vasant Narasimhan M.D. and employs about 75,267 people. At a market capitalization of $288.61 billion, it ranks among the largest companies in the US market.
Its SEC Central Index Key (CIK) is 0001114448, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Novartis do?
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Business description based on the company's public filings.
Company information
- Legal name
- Novartis AG
- Ticker
- NYSE: NVS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vasant Narasimhan M.D.
- Employees
- 75,267
- Headquarters
- Lichtstrasse 35, Basel, Switzerland
- Phone
- 41 61 324 11 11
- Website
- novartis.com
- Market cap
- $288.61B
- SEC CIK
- 0001114448
Companies similar to Novartis
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs NVS |
| MRKMerck & Company Inc. | 133.72 | +0.69% | $329.65B | vs NVS |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs NVS |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs NVS |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs NVS |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs NVS |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs NVS |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs NVS |